Cetuximab单抗生物相似药市场规模、份额和增长分析：按适应症/治疗应用、剂型、治疗策略、最终用户和地区划分 - 行业预测，2026-2033年

2024 年全球Cetuximab单抗生物相似药市值为 1.254 亿美元，预计到 2033 年将从 2025 年的 1.4923 亿美元增长至 6.01 亿美元，在预测期（2026-2033 年）内复合年增长率为 19.0%。

Cetuximab单抗生物相似药市场的主要驱动因素是原厂药专利到期以及支付方降低癌症治疗成本的压力日益增大，这为生物类似药的研发提供了强大的经济奖励。由于Cetuximab单抗在生物製药癌症治疗成本中占据相当大的比例，生物相似药开发商旨在透过提供价格更低的替代药物来吸引註重预算的消费者，从而改善患者的用药可及性，并帮助医院在更紧张的预算下运作。受采购政策和生产效率影响的价格趋势对市场成长至关重要，因为较低的价格会鼓励患者儘早开始治疗，从而提高治疗率。此外，人工智慧正在革新定价策略，它将细粒度的临床和支付方数据转化为可执行的洞察，优化竞标提案，并实现个人化方法以利用区域市场趋势，最终推动市场扩张。

全球Cetuximab单抗生物相似药市场驱动因素

全球Cetuximab生物相似药市场的发展得益于监管流程的改进，这些改进最大限度地减少了研发者的不确定性，并明确了产品等效性的预期。这项改进将鼓励加大投资，并加速生物相似药研发管线的进展。统一的指南和清晰的核准框架，透过明确具体的临床和分析要求，奖励製造商积极参与研发，从而缩短研发週期并降低监管风险。此外，这些流程的完善确保了品质和安全评估的一致性，增强了包括临床医生和支付方在内的相关人员的信心。这有助于西Cetuximab生物相似药从研发阶段成功过渡到市场，并最终获得更广泛的认可。

全球Cetuximab单抗生物相似药市场面临的限制因素

全球Cetuximab单抗生物相似药市场面临诸多限制因素，主要源自于专利和诉讼方面的挑战，这些挑战阻碍了市场准入并延缓了商业化进程。围绕智慧财产权的法律不确定性和旷日持久的纠纷耗尽了生物相似药研发公司的资源，迫使它们将精力集中在法律辩护而非研发上。这种情况减缓了新产品的上市速度，并抑制了市场竞争。此外，旷日持久的法律诉讼也可能吓退投资者和商业伙伴，导致参与企业数量减少，并限制了扩大患者获得西Cetuximab单抗生物类似药的机会。

全球Cetuximab单抗生物相似药市场趋势

全球Cetuximab单抗生物相似药市场正经历显着成长，这主要得益于保险公司和医疗服务提供者接受度的不断提高。这种转变促使更多患者将生物相似药纳入健保覆盖范围，简化采购流程，并扩大了这些药物的可近性。生产商正致力于打造有效的价值提案、开展患者支持项目，并开展医护人员宣传活动，这些对于将生物类似药整合到标准治疗通讯协定中至关重要。此外，优先考虑成本效益高的疗法的政策趋势正在加速生物相似药的普及，而与经销商和当地企业的策略合作正在加强分销网络，尤其是在服务不足的市场，从而改善了供应，并确保了有需要的患者能够获得公平的治疗。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

关键市场分析

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场魅力指数
• PESTLE分析
• 监理情势

全球Cetuximab单抗生物相似药市场规模：依适应症/治疗应用划分

• 转移性大肠直肠癌（mCRC）
• 头颈部鳞状细胞癌（HNSCC）

全球Cetuximab单抗生物相似药市场规模：按剂型划分

• 静脉输液

全球Cetuximab单抗生物相似药市场规模：依治疗策略划分

• 主要治疗
• 二线治疗/联合治疗

全球Cetuximab单抗生物相似药市场规模：依最终用户划分

• 癌症专科医院
• 门诊化疗中心
• 学术研究机构

全球Cetuximab单抗生物相似药市场规模：按地区划分

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太国家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲国家

竞争资讯

• 前五大公司对比
• 主要企业2025年的市场定位
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市场占有率分析，2025 年
• 主要企业的完整公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 销售收入年比比较（2023-2025 年）

主要企业简介

• Amgen Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Samsung Bioepis
• Mylan NV
• Teva Pharmaceutical Industries Ltd.
• Celltrion Healthcare Co., Ltd.
• Sandoz International GmbH
• Gensight Biologics
• AbbVie Inc.
• Biosimilars Inc.
• Biocon Limited
• UCB Pharma
• Cipla Limited
• Fresenius Kabi AG
• Wockhardt Ltd.
• Zydus Cadila
• Intas Pharmaceuticals
• Coherus BioSciences, Inc.
• Novartis AG

结论与建议

Global Cetuximab Biosimilar Market size was valued at USD 125.4 Million in 2024 and is poised to grow from USD 149.23 Million in 2025 to USD 600.1 Million by 2033, growing at a CAGR of 19.0% during the forecast period (2026-2033).

The cetuximab biosimilar market is primarily driven by the expiration of originator patents and increased payer pressure to reduce oncology costs, creating strong economic incentives for biosimilar development. As cetuximab is a significant contributor to biological oncology spending, biosimilar developers aim to attract budget-conscious consumers by providing lower-cost alternatives, thereby enhancing patient access and enabling hospitals to operate within tighter budgets. Pricing dynamics influenced by procurement policies and manufacturing efficiencies are essential for growth, as lower prices encourage early initiation of therapy and increase patient treatment volumes. Additionally, AI is revolutionizing pricing strategies by transforming segmented clinical and payer data into actionable insights, optimizing tender proposals, and allowing for tailored approaches to capitalize on local market dynamics, ultimately driving market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cetuximab Biosimilar market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cetuximab Biosimilar Market Segments Analysis

Global cetuximab biosimilar market is segmented by indication/therapeutic use, dosage form, line of treatment, end-user and region. Based on indication/therapeutic use, the market is segmented into Metastatic Colorectal Cancer (mCRC) and Head and Neck Squamous Cell Carcinoma (HNSCC). Based on dosage form, the market is segmented into Intravenous (IV) Infusion. Based on line of treatment, the market is segmented into First-line Therapy and Second-line/Combination Therapy. Based on end-user, the market is segmented into Oncology Specialty Hospitals, Outpatient Chemotherapy Centers and Academic Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cetuximab Biosimilar Market

The global Cetuximab biosimilar market is driven by enhanced regulatory pathways that minimize uncertainty for developers, providing clearer expectations regarding product comparability. This improvement fosters increased investment and accelerates advancements in biosimilar pipelines. Harmonized guidelines and clear approval frameworks incentivize manufacturers to engage in development by outlining specific clinical and analytical requirements, which can lead to shortened timelines and reduced regulatory risks. Additionally, these defined pathways enhance confidence among stakeholders, including clinicians and payers, by ensuring consistent quality and safety assessments. This, in turn, facilitates the transition from development efforts to successful market introductions and wider acceptance of Cetuximab biosimilars.

Restraints in the Global Cetuximab Biosimilar Market

The global cetuximab biosimilar market faces significant restraints primarily due to patent and litigation challenges that hinder market entry and delay the commercialization process. Legal uncertainties and prolonged disputes surrounding intellectual property rights can divert considerable resources from biosimilar sponsors, forcing them to focus on legal defense instead of development. This situation slows down new product introductions and stifles market competition. Additionally, the potential for lengthy legal battles deters investors and commercial partners, thereby reducing the number of market entrants and constraining the overall capacity to enhance patient access to cetuximab biosimilars.

Market Trends of the Global Cetuximab Biosimilar Market

The global cetuximab biosimilar market is experiencing a significant upward trend driven by increasing acceptance among payers and healthcare institutions. This shift is enhancing formulary inclusion and streamlining procurement processes, enabling broader accessibility to these biosimilars. Manufacturers are focusing on effective value messaging, patient support initiatives, and educational outreach for healthcare professionals, which are crucial for their integration into standard care protocols. Additionally, policy trends prioritizing cost-effective therapeutics are fostering uptake, while strategic partnerships with distributors and local entities are enhancing distribution networks, especially in underserved markets, thereby improving availability and equity in care for patients who need it.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Cetuximab Biosimilar Market Size by Indication/Therapeutic Use & CAGR (2026-2033)

• Market Overview
• Metastatic Colorectal Cancer (mCRC)
• Head and Neck Squamous Cell Carcinoma (HNSCC)

Global Cetuximab Biosimilar Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Intravenous (IV) Infusion

Global Cetuximab Biosimilar Market Size by Line of Treatment & CAGR (2026-2033)

• Market Overview
• First-line Therapy
• Second-line/Combination Therapy

Global Cetuximab Biosimilar Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Oncology Specialty Hospitals
• Outpatient Chemotherapy Centers
• Academic Research Institutes

Global Cetuximab Biosimilar Market Size & CAGR (2026-2033)

• North America (Indication/Therapeutic Use, Dosage Form, Line of Treatment, End-User)
  • US
  • Canada
• Europe (Indication/Therapeutic Use, Dosage Form, Line of Treatment, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication/Therapeutic Use, Dosage Form, Line of Treatment, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication/Therapeutic Use, Dosage Form, Line of Treatment, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication/Therapeutic Use, Dosage Form, Line of Treatment, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Healthcare Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gensight Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biosimilars Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations